Agomab Spain S.l.u.
Clinical trials sponsored by Agomab Spain S.l.u., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Radioactive tracer reveals how potential Crohn's drug moves through the body Results expected Sep 2026 (estimated)
-
New drug could unblock Crohn's-Related bowel narrowing without surgery
Disease control Recruiting nowThis trial tests an experimental drug called ontunisertib in people with Crohn's disease who have developed scarred, narrowed sections in their bowel that cause pain and blockages. The goal is to see if the drug can reopen these narrowed areas, potentially reducing symptoms and t…
Phase 2 • Sponsor: Agomab Spain S.L.U. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Radioactive tracer reveals how potential Crohn's drug moves through the body
Knowledge-focused Recruiting nowThis trial in 8 healthy men aged 30–65 examines how the body absorbs, breaks down, and eliminates ontunisertib, an experimental oral drug for fibrostenotic Crohn's disease. Participants receive a single dose of the drug with a radioactive label, allowing researchers to track its …
Phase 1 • Sponsor: Agomab Spain S.L.U. • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC